title: Acute 5-HT7 receptor activation increases NMDA-evoked currents and differentially alters NMDA receptor subunit phosphorylation and trafficking in hippocampal neurons.
abstract: BACKGROUND
  N-methyl-D-aspartate (NMDA) receptors are regulated by several G protein-coupled receptors (GPCRs) as well as receptor tyrosine kinases. Serotonin (5-HT) type 7 receptors are expressed throughout the brain including the thalamus and hippocampus. Long-term (2-24 h) activation of 5-HT7 receptors promotes the expression of neuroprotective growth factor receptors, including the platelet-derived growth factor (PDGF) β receptors which can protect neurons against NMDA-induced neurotoxicity.
  
  
  RESULTS
  In contrast to long-term activation of 5-HT7 receptors, acute (5 min) treatment of isolated hippocampal neurons with the 5-HT7 receptor agonist 5-carboxamidotryptamine (5-CT) enhances NMDA-evoked peak currents and this increase in peak currents is blocked by the 5-HT7 receptor antagonist, SB 269970. In hippocampal slices, acute 5-HT7 receptor activation increases NR1 NMDA receptor subunit phosphorylation and differentially alters the phosphorylation state of the NR2B and NR2A subunits. NMDA receptor subunit cell surface expression is also differentially altered by 5-HT7 receptor agonists: NR2B cell surface expression is decreased whereas NR1 and NR2A surface expression are not significantly altered.
  
  
  CONCLUSIONS
  In contrast to the negative regulatory effects of long-term activation of 5-HT7 receptors on NMDA receptor signaling, acute activation of 5-HT7 receptors promotes NMDA receptor activity. These findings highlight the potential for temporally differential regulation of NMDA receptors by the 5-HT7 receptor.
authors.forename: Maryam S
authors.initials: MS
authors.lastname: Vasefi
authors.forename: Kai
authors.initials: K
authors.lastname: Yang
authors.forename: Jerry
authors.initials: J
authors.lastname: Li
authors.forename: Jeff S
authors.initials: JS
authors.lastname: Kruk
authors.forename: John J
authors.initials: JJ
authors.lastname: Heikkila
authors.forename: Michael F
authors.initials: MF
authors.lastname: Jackson
authors.forename: John F
authors.initials: JF
authors.lastname: MacDonald
authors.forename: Michael A
authors.initials: MA
authors.lastname: Beazely
mesh_terms: D000577:Amides / Q000494:pharmacology; D000818:Animals; D006624:Hippocampus / Q000166:cytology*; D015640:Ion Channel Gating / Q000187:drug effects*; D008954:Models, Biological; D016202:N-Methylaspartate / Q000494:pharmacology*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D010768:Phosphoserine / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology; D021122:Protein Subunits / Q000378:metabolism*; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*; D011985:Receptors, Serotonin / Q000378:metabolism*; D012701:Serotonin / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: C523823:4-(2-diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide; D000577:Amides; D010879:Piperazines; D021122:Protein Subunits; D016194:Receptors, N-Methyl-D-Aspartate; D011985:Receptors, Serotonin; C104425:serotonin 7 receptor; D010768:Phosphoserine; D012701:Serotonin; D016202:N-Methylaspartate; C047087:5-carboxamidotryptamine